Patiromer not checked

Vifor Pharma, Inc. · Relypsa, Inc. · RLY5016 for Oral Suspension · RLY5016

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
14 in total · 5 in the EU
Targets
—
None known yet

What this is

How it works
Potassium Binder FDA class
How it’s given
“Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split”In the company’s words, NCT05766839 on ClinicalTrials.gov
Tested for
Hyperkalemia
Main trialPhase 2
“A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.”In the company’s words, NCT05766839 on ClinicalTrials.gov
Other names
Veltassa · RLY5016 for Oral Suspension · RLY5016

Other drugs for Hyperkalemia

All 3 drugs for Hyperkalemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials14

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 1 Dec 2029 Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
Phase 4Completed Jul 2016 Patiromer With or Without Food for the Treatment of Hyperkalemia
Phase 3Completed Jul 2013 A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
Phase 3Completed 2 Sep 2021 Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Phase 2Terminated Dec 2008 An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
Phase 2Completed Nov 2009 Evaluation of Patiromer in Heart Failure Patients
Phase 2Completed Sep 2010 Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
Phase 2Completed May 2013 Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
Phase 2Completed 27 Nov 2018 Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
Phase 2Terminated 13 Jan 2021 Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
Phase 2Ended not given Double-blind, placebo-controlled clinical trial to determine the effect of Patiromer on vascular function and its relationship with mineral metabolism parameters
Phase 3Ended not given A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dialysis patients with CKD stage IIIB to Vrandomized to Patiromer or placebo
Phase 4Authorised not given PROMISE: Potassium correction for RAAS Optimization in Chronic Kidney Disease
Phase 3Authorised not given Impact of Patiromer treatment on dietary Potassium intake restriction and health-related quality of life and nutrition in patients on Chronic Dialysis Therapy: a Double-Blind, Prospective, Randomized, Placebo-Controlled, Pilot Trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Patiromer

Following is part of Solo: you see every change to Patiromer the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in